Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States

By sjmartinez • April 11, 2025

Luo Y, Assassi S, Mayes MD, Frech TM, Steen VD, Richardson C, Chung L, Sandorfi N, VanBuren JM, Harding M, Alvey JS, Skaug B, McMahan Z, Lakin KS, Zahn C, Bracken SJ, Lebiedz-Odrobina DJ, Molitor JA, Evnin LB, Moore DF, Shah A, Castelino FV, Volkmann ER, Hant FN, Makol A, Shah AA, Hummers LK, Gordon JK, Khanna D, Bernstein EJ. Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc. 2025 Apr 10. doi: 10.1513/AnnalsATS.202410-1045RL. Epub ahead of print. PMID: 40208257.

Tags: Publications, Rheumatology

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton[...]

Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry

Agrawal P, Kumar P, Ali B, Nabeela S, Ikeh MAC, Morschhäuser J, Andes DR, Nobile CJ, Prasad R, Uppuluri P, Panwar SL. Lem3, a phospholipid[...]

Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer

Yeh MW. Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer. Thyroid. 2026[...]